Extraocular Muscle Enlargement in Growth Hormone–Secreting Pituitary Adenomas

References

1. 1.↵
   1. Holdaway IM,
   2. Rajasoorya C

   . Epidemiology of acromegaly. Pituitary 1999;2:29–41 doi:10.1023/A:1009965803750 pmid:11081170

   CrossRefPubMed
2. 2.↵
   1. Vilar L,
   2. Vilar CF,
   3. Lyra R, et al

   . Acromegaly: clinical features at diagnosis. Pituitary 2017;20:22–32 doi:10.1007/s11102-016-0772-8 pmid:27812777

   CrossRefPubMed
3. 3.↵
   1. Giustina A,
   2. Bronstein MD,
   3. Chanson P, et al

   . Staging and managing patients with acromegaly in clinical practice: baseline data from the SAGIT® validation study. Pituitary 2019;22:476–87 doi:10.1007/s11102-019-00977-5 pmid:31338660

   CrossRefPubMed
4. 4.↵
   1. Lacey B,
   2. Chang W,
   3. Rootman J

   . Nonthyroid causes of extraocular muscle disease. Surv Ophthalmol 1999;44:187–213 doi:10.1016/s0039-6257(99)00101-0 pmid:10588439

   CrossRefPubMedWeb of Science
5. 5.↵
   1. Zafar A,
   2. Jordan DR

   . Enlarged extraocular muscles as the presenting feature of acromegaly. Ophthalmic Plast Reconstr Surg 2004;20:334–36 doi:10.1097/01.iop.0000132179.74910.79 pmid:15266156

   CrossRefPubMed
6. 6.↵
   1. Shimon I,
   2. Adnan Z,
   3. Gorshtein A, et al

   . Efficacy and safety of long-acting pasireotide in patients with somatostatin-resistant acromegaly: a multicenter study. Endocrine 2018;62:448–55 doi:10.1007/s12020-018-1690-5 pmid:30051198

   CrossRefPubMed
7. 7.↵
   1. Van Esdonk MJ,
   2. van Zutphen EJ,
   3. Roelfsema F, et al

   . How are growth hormone and insulin-like growth factor-1 reported as markers for drug effectiveness in clinical acromegaly research? A comprehensive methodologic review. Pituitary 2018;21:310–22 doi:10.1007/s11102-018-0884-4 pmid:29605877

   CrossRefPubMed
8. 8.↵
   1. Giustina A,
   2. Barkan A,
   3. Beckers A, et al

   . A consensus on the diagnosis and treatment of acromegaly comorbidities: an update. J Clin Endocrinol Metab 2020;105:dgz096 doi:10.1210/clinem/dgz096 pmid:31606735

   CrossRefPubMed
9. 9.↵
   1. Ozgen A,
   2. Aydingöz U

   . Normative measurements of orbital structures using MRI. J Comput Assist Tomogr 2000;24:493–96 doi:10.1097/00004728-200005000-00025 pmid:10864092

   CrossRefPubMedWeb of Science
10. 10.↵
    1. Pozzo G,
    2. Boschi MC

    . Extraocular muscle enlargement in acromegaly. J Comput Assist Tomogr 1982;6:706–707 doi:10.1097/00004728-198208000-00007 pmid:7119187

    CrossRefPubMedWeb of Science
11. 11.↵
    1. Heireman S,
    2. Delaey C,
    3. Claerhout I, et al

    . Restrictive extraocular myopathy: a presenting feature of acromegaly. Indian J Ophthalmol 2011;59:517–19 doi:10.4103/0301-4738.86330 pmid:22011505

    CrossRefPubMed
12. 12.↵
    1. Mehra M,
    2. Mohsin M,
    3. Sharma P, et al

    . Epiphora and proptosis as a presenting complaint in acromegaly: report of two cases with review of literature. Indian J Endocrinol Metab 2013;17(Suppl 1);S149–51 doi:10.4103/2230-8210.119553] pmid:24251139

    CrossRefPubMed
13. 13.↵
    1. Schwarz F,
    2. der Kinderen PJ,
    3. Houtstra-Lanz M

    . Exophthalmos-producing activity in the serum and in the pituitary of patients with Cushing’s syndrome and acromegaly. J Clin Endocrinol Metab 1962;22:718–25 doi:10.1210/jcem-22-7-718 pmid:13909760

    CrossRefPubMedWeb of Science
14. 14.↵
    1. Geraedts VJ,
    2. Andela CD,
    3. Stalla GK, et al

    . Predictors of quality of life in acromegaly: No consensus on biochemical parameters. Front Endocrinol (Lausanne) 2017;8:40 doi:10.3389/fendo.2017.00040 pmid:28316591

    CrossRefPubMed
15. 15.↵
    1. Kyriakakis N,
    2. Lynch J,
    3. Gilbey SG, et al

    . Impaired quality of life in patients with treated acromegaly despite long-term biochemically stable disease: results from a 5-years prospective study. Clin Endocrinol (Oxf) 2017;86:806–15 doi:10.1111/cen.13331 pmid:28316090

    CrossRefPubMed
16. 16.↵
    1. Patrinely JR,
    2. Osborn AG,
    3. Anderson RL, et al

    . Computed tomographic features of nonthyroid extraocular muscle enlargement. Ophthalmology 1989;96:1038–47 doi:10.1016/S0161-6420(89)32785-0 pmid:2771351

    CrossRefPubMedWeb of Science
17. 17.↵
    1. Douglas RS,
    2. Kahaly GJ,
    3. Patel A, et al

    . Teprotumumab for the treatment of active thyroid eye disease. N Engl J Med 2020;382:341–52 doi:10.1056/NEJMoa1910434 pmid:31971679

    CrossRefPubMed
18. 18.↵
    1. Ozgen A,
    2. Ariyurek M

    . Normative measurements of orbital structures using CT. AJR Am J Roentgenol 1998;170:1093–96 doi:10.2214/ajr.170.4.9530066 pmid:9530066

    CrossRefPubMedWeb of Science